Skip to main content

Table 2 Primary clinical outcomes

From: Antiviral treatment perspective against Borna disease virus 1 infection in major depression: a double-blind placebo-controlled randomized clinical trial

Patients N = 33Differences A vs. PaPatients with Amantadine(A) N = 16Patients with Placebo (P) N = 17
Response 136
Non-response 311
Response rate (%) 13/16 = 0.8125 (81.25%)6/17 = 0.3529 (35.29%)
Statistical significance (defined as p < 0.05)p = 0.003  
Absolute response difference81.25–35.29 = 45.96%  
Relative response (RR)81.25/35.29 = 2.302  
Odds 13/3 = 4.336/11 = 0.55
Odds ratio (OR)4.33/0.55 = 7.872  
Effect size of difference (expressed as Cohen’s d)d = 1.0461  
Effect size of difference (expressed as Hedges’s g)g = 1.0175  
Effect size of association (correlation coefficient r)r = 0.463  
  1. aPrimary outcome defined as changes between pre-treatment scores and scores at week 7 of the HAMD (DHAMD). Clinical endpoint defined as reduction of HAMD ≥25%. Time endpoint: 7 weeks